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Purpose. The aim of this study was to analyse the levels of interleukin-6 (IL-6) and interleukin-8 (IL-8) in gingival crevicular ﬂuid
(GCF) of patients with chronic periodontitis prior to and following surgical and/or nonsurgical periodontal therapy for a period
of 32 weeks. Methods. GCF samples were obtained from 24 nondiseased and 72 diseased sites of 12 periodontal patients prior to
as well as at 6, 16, and 32 weeks following non-surgical and surgical periodontal therapy. IL-6 and IL-8 levels were determined
by enzyme-linked immunosorbent assay (ELISA). Results. Periodontal treatment improved all clinical parameters. Both treatment
modalities resulted in similar IL-6 as well as IL-8 levels. Mean IL-6 and IL-8 concentrations were signiﬁcantly higher in non-
diseased compared to diseased sites and increased signiﬁcantly following treatment in diseased sites. Mean total amounts of IL-6
and IL-8 (TAIL-6, TAIL-8) did not diﬀer signiﬁcantly between diseased and nondiseased sites, while following therapy TAIL-8
levels decreased signiﬁcantly. Conclusions. The data suggest that periodontal therapy reduced the levels of IL-8 in GCF. However, a
strong relationship between IL-6, IL-8 amounts in GCF and periodontal destruction and inﬂammation was not found.
1.Introduction
Chronic periodontitis is an inﬂammatory disease aﬀecting
the supporting tissues of teeth. The expression of the disease
results from the interaction of host defense mechanisms,
microbialagents,environmental,andgeneticfactors.Various
compounds,suchascytokines,havebeendetectedingingival
crevicular ﬂuid (GCF) [1] and may be especially beneﬁcial
for diagnosing current periodontal status and addressing the
eﬀects of periodontal treatment [2].
IL-8 belongs to the interleukin-8 supergene family
that includes small peptides with chemotactic activity for
speciﬁc types of leukocyte populations [3]. This cytokine is
induced and secreted by many cells, such as monocytes [4],
lymphocytes [5], ﬁbroblasts [6], epithelial, and endothelial
cells [7, 8]a sw e l la sb ys y n o v i a lc e l l s[ 6]. IL-8 attracts and
activates polymorphonuclear leukocytes (PMN) in inﬂam-
matory regions [9, 10]. It induces the adhesion of PMN to
endothelial cells and their transendothelial migration [11]a s
well as the release of granule enzymes from these cells [12].
In periodontal patients, IL-8 has been reported in both
GCFandperiodontaltissues.McGeeetal.[13]foundthatIL-
8concentrationsweresigniﬁcantlyhigheringingivaadjacent
to probing pocket depth ≤3mm and lowest adjacent to
>6mm sulci. In GCF, Chung et al. [14] suggested that
the absence of a direct relationship between IL-8 and
PMN recruitment may characterize individuals at risk for
progression of periodontitis, while in another study [15], no
signiﬁcant diﬀerence in GCF IL-8 levels between localized
juvenile periodontitis and healthy subjects was shown.
According to Mathur et al. [16], the total amount of IL-8 was
signiﬁcantly higher in diseased compared to healthy sites.
Interleukin-6 (IL-6) is an important cytokine involved
in the regulation of host response to tissue injury and
infection [17]. It is produced by a variety of cells, such as
monocytes, ﬁbroblasts [18], osteoblasts [19], and vascular2 International Journal of Dentistry
endothelial cells [20] in response to inﬂammatory challenges
[21]. It plays an important role in B-cell diﬀerentiation
[22] and in T-cell proliferation [23], while IL-6, synergistic
with interleukin-1β (IL-1β), induces bone resorption [19].
However, it has also been reported that it can increase the
production of tissue inhibitors of matrix metalloproteinases
(TIMP)[24,25],suppressesIL-1expression[26],whileitcan
inducethesynthesisofIL-1receptorantagonist(IL-1Ra)and
the release of soluble TNF receptors [27] suggesting its anti-
inﬂammatory properties.
In patients with refractory periodontitis, active sites—
those displaying loss of attachment >2.1mm in 3 months—
revealed signiﬁcantly higher GCF IL-6 levels than inactive
ones [28]. In HIV-1-infected patients, GCF IL-6 levels were
increased compared to uninfected periodontal patients [29].
According to Guillot et al. [30], in periodontal sites requiring
surgery (unresolved sites), GCF IL-6 levels were signiﬁcantly
lower compared to those at resolved sites (not requiring
surgery). In gingival tissues, Prabhu et al. [31]r e p o r t e d
that expression of IL-6 m RNA was signiﬁcantly higher in
diseased tissues compared to healthy ones in periodontitis
patients.
The purpose of this study was to examine the GCF levels
of IL-6 and IL-8 in periodontal sites with varying degrees of
destruction and inﬂammation of periodontal patients prior
to and following surgical and/or nonsurgical periodontal
therapy.
2.MaterialsandMethods
Patients with chronic periodontitis were recruited into this
randomised, longitudinal, split-mouth, interventional study,
from patients referred to the Department of Periodontology,
Aristotle University of Thessaloniki. All of them were
Caucasians. The selection criteria were (1) patients aged 35–
65 years for males and 35–45 years for females; (2) good
general health with no history of systemic disease; (3) no
medication was taken; (4) no periodontal therapy received
in the preceding 1 year; (5) more than 20 remaining teeth;
(6) moderate to advanced periodontal disease as evidenced
by multiple sites with a probing depth of 5mm or more,
extensive radiographic bone loss and bleeding on gentle
probing; (7) pregnant or lactating females were excluded.
Postmenopausal females or others on estrogen therapy were
excluded [32]. Informed consent was obtained from each
patient prior to enrolment in this study, and ethical approval
was obtained from the Aristotle University of Thessaloniki
ethics committee.
In each patient, two quadrants of either the mandible
or maxilla were randomly assigned as experimental. In each
experimental quadrant, 4 periodontal interproximal sites
in single-rooted teeth were selected. Three sites displaying
probing pocket depths (PD) ≥ 5mm and a gingival index
(GI) [33]o f2o r3w e r ed e ﬁ n e da sd i s e a s e ds i t e sa n d1
site with PD ≤ 3mm and GI = 0o r1w a sd e ﬁ n e da s
a nondiseased control site. A total of 96 test sites were
included in the study, 72 of them as diseased and 24
as nondiseased sites. Sites in one experimental quadrant
receivednonsurgicalperiodontaltreatmentconsistingoforal
hygiene instructions, scaling and root surface debridement,
while the contralateral sites received nonsurgical followed by
surgical periodontal treatment, using a modiﬁed Widman
ﬂap [34]. At 6, 16, and 32 weeks following treatment, the
dentition received supragingival polishing with a rubber cup
and pumice.
Prior to as well as 6, 16, and 32 weeks following per-
iodontal therapy, a GCF sample was taken from each test
site, and IL-6 and IL-8 were quantiﬁed. The following
clinical measurements were also evaluated: (1) plaque index
(PlI), according to Silness and L¨ oe [35], (2) gingival index
(GI), according to L¨ oe [33], (3) probing pocket depth
(PD), and (4) clinical attachment loss (CAL), to the nearest
millimeter with a Williams probe. The PD score in each
site was evaluated in duplicate and mean values were, then,
recorded. The same examiner performed all measurements.
In all patients, individual acrylic stents were fabricated with
reference grooves as reference points for the above clinical
measurements and for GCF sampling.
Patients were all asked about their smoking habits
and were classiﬁed as smokers or never-smokers. Former
smokers, that is, patients who had stopped the habit, were
not included in this study.
2.1. GCF Sampling. Both experimental quadrants were iso-
latedwithcottonrolls,andclinicallydetectablesupragingival
plaque was removed using a curette without touching the
marginal gingiva. Sites were gently dried with an air syringe,
and a single sterile paper strip (Periopaper, OraFlow, Plain
View, NY, 11803, USA) for each examined site was inserted
into the gingival crevice, until mild resistance was felt and
was kept there for 30s. Strips contaminated by bleeding were
discarded and GCF sampling was repeated the following
day. The amount of GCF collected was quantitated using
Periotron 6000 (Siemens Medical Systems, Inc., Iselin, NJ,
USA), which had been calibrated with 1:5 diluted serum
[36]. Each paper strip was placed into a coded sealed plastic
tube containing 250μL phosphate buﬀered saline (PBS). The
samples were left at 4◦C for 2h and, then, they were frozen at
−70
◦C and stored until cytokine analysis.
2.2.Enzyme-LinkedImmunosorbentAssay(ELISA). GCFwas
eluted from each ﬁlter paper strip into PBS as follows: before
the IL-6 and IL-8 assays were performed, samples were left
at 4◦C for 2h. Then, each strip was lifted to the surface of
the eluent, and another 350μL of PBS was added to the strip
(600μL ﬁnal volume). Samples were, then, refrigerated at
4◦C for another 20min and centrifuged at 10,000rpm for
10min. Finally, the strips were discarded.
Commercial ELISA kits (R and D systems, Abingdon,
Oxon, UK) were used to analyse IL-6 and IL-8 levels. The
kit employs a quantitative “sandwich” enzyme immunoas-
say technique. A murine antihuman monoclonal antibody
speciﬁc for IL-6 and IL-8 was precoated onto a 96-well
microplate. Any IL-6 or IL-8 present was bound by the
immobilised antibody. After washing of unbound proteins,
an enzyme-linked (horseradish peroxidase) polyclonal anti-
body (200μL) speciﬁc for IL-6 or IL-8 (goat antihuman) was
added to each well. Then, 200μL of a substrate solution wasInternational Journal of Dentistry 3
added and any colour developed was proportional to the
amountofIL-6orIL-8,respectively,boundintheinitialstep.
The intensity of the colour (optical density) was measured
using a microplate reader at 450nm (wavelength correction
set to 540nm) within 30min. A standard curve was prepared
byplottingtheconcentrationoftheIL-6(standards300,100,
50, 25, 12.5, 6.25, 3.12, and 0pg/mL) or the concentration of
the IL-8 standards (2000, 1000, 500, 250, 125, 62.5 31.2, and
0pg/mL) against their optical density and the concentration
of IL-6 or IL-8, respectively, was determined. Then, the pg
of IL-6 or IL-8 in each sample (total amount) was calculated
and the IL-6 or IL-8 concentration (pg/mL) was determined
by dividing the amount of IL-6 or IL-8 by the GCF volume
(μL). The ELISA assays were run in duplicate; mean values
were used to calculate total amounts and concentrations
of each cytokine. The minimum detectable level of IL-6
(sensitivity of ELISA) was typically less than 0.70pg/mL,
while the minimum detectable level of IL-8 was less than
10pg/mL.
2.3. Statistical Analysis. Data analysis was performed using
the statistical package SPSS ver. 11.5 (SPSS Inc., Chicago
Illsion, USA). For all time intervals, the mean cytokine
and clinical values from the 2 healthy and the 6 diseased
sites in each patient were used for the purposes of analysis.
Negative samples were considered zero for the calculations.
Diﬀerences in cytokine levels between diseased and nondis-
eased sites as well as between smokers and nonsmokers were
evaluated by the Mann-Whitney test. In each case, the level
ofsigniﬁcancewassetat P<0.05. Comparison oftheclinical
measurementspriortoandfollowingtherapywasperformed
by Wilcoxon Signed Ranks test. The same test was used to
investigate the diﬀerences in GCF volume and in GCF IL-
6o rI L - 8l e v e l sb e f o r ea sw e l la s6 ,1 6 ,a n d3 2w e e k sf o l -
lowing periodontal therapy. Finally, the Kendall’s correlation
coeﬃcient was used to study the correlation between IL-6,
IL-8 levels, and clinical parameters. A Bonferroni correction
for all multiple comparisons was applied. To assess the
distribution of the data, the Kolmogorov-Smirnov test was
used.
3. Results
Twelve volunteers (7 females and 5 males, mean age 45.4
years) took part in this study.
3.1. Frequency of Detection. Interleukin-6 was detected in
GCF samples from 63/72 diseased sites (87.5%) and from
23/24 (95.83%) nondiseased sites, at baseline. The respective
valuesatthe6thweekfollowingtherapywere60/72(83.33%)
and 22/24 (91.66%), at the 16th week 57/72 (79.17%) and
23/24 (95.83%), while at the 32nd week were 64/72 (88.89%)
and 23/24 (95.83%).
At baseline, interleukin-8 was detected in GCF samples
from 71/72 diseased sites (98.61%) and from all the nondis-
eased sites (100%). The respective values following therapy
were: 71/72 (98.61%) and 23/24 (95.83%) at the 6th week,
70/72 (97.22%) and 23/24 (95.83%) at the 16th week, and,
ﬁnally,71/72(98.61%)and23/24(95.83%)atthe32ndweek.
3.2. GCF Volumes. The GCF volume, expressed in μL, of 72
diseasedand24nondiseasedsitesbothpriortoandfollowing
therapy are presented in Table 1. Mean GCF values were
signiﬁcantly higher in diseased compared to nondiseased
sites (P<0.01 at baseline, P<0.05 following therapy).
Periodontal therapy resulted in a signiﬁcant decrease in GCF
volume in both diseased and nondiseased sites (P<0.01 and
P<0.05, resp.).
3.3. Concentration and Total Amount of IL-6 and IL-8. The
concentration (IL-6, IL-8) and the total amount (TAIL-
6, TAIL-8) of interleukin-6 and -8 in GCF expressed in
pg/μL and pg/30s, respectively, are presented in Table 2.
Mean IL-6 concentration values were signiﬁcantly higher
in nondiseased compared to diseased sites both prior to
and following periodontal treatment (at baseline P<0.01,
post-treatment P<0.05). Mean TAIL-6 values did not
diﬀer signiﬁcantly between diseased and nondiseased sites.
Periodontal treatment resulted in signiﬁcant increase of IL-6
concentration in diseased sites (P<0.01 at 6 weeks), while
in nondiseased sites IL-6 levels remained almost unchanged.
Following therapy, TAIL-6 levels were slightly reduced at
6 weeks, but at 32 weeks they were increased in almost
pretreatment levels.
Mean IL-8 concentration was signiﬁcantly higher in
nondiseased compared to diseased sites (P<0.01 at baseline
and at 6 weeks). Following therapy, IL-8 concentration
increased signiﬁcantly (P<0.05 at 6 and 16 weeks) in
diseased sites, while in nondiseased it displayed only a slight
increase. Mean TAIL-8 levels were similar in diseased and
nondiseased sites. TAIL-8 decreased signiﬁcantly following
therapy (P<0.01 at 6 weeks).
Both treatment modalities, surgical and nonsurgical
periodontal treatment, resulted in similar IL-6 as well as IL-8
total amounts and concentrations at each interval following
treatment.
A strong correlation (P<0.05) was also found between
IL-6 and IL-8 concentrations (Table 3).
3.4. Clinical Parameters. In diseased sites, periodontal treat-
ment led to improvements in all clinical parameters
(Table 2). At 6 weeks, mean PD, CAL, PlI, and GI scores were
signiﬁcantly decreased (P<0.01). The PlI and GI scores
were also decreased (P<0.05) at 16 weeks. However, by
32 weeks after-therapy an increase in PD, CAL, GI, and PlI
scores was noted (P<0.05 for GI and PlI). In nondiseased
sites, periodontal therapy resulted in a signiﬁcant decrease
only in PlI and GI scores at 6 weeks (P<0.01) and at 16
weeks (P<0.05). At 32 weeks, an increase in PlI score was
noted (P<0.05).
The comparison between IL-6, IL-8 levels, and clinical
parameters revealed strong negative correlations between IL-
6 concentration and GI, PD and CAL (Table 4).
3.5.SmokingStatus. Theconcentrationandthetotalamount
of IL-6 and IL-8 as well as the mean values of PD and
CAL in seven smokers and ﬁve nonsmokers are presented in
Table 5. In all sites, TAIL-6 levels were higher in nonsmokers
than in smokers both prior to and following treatment4 International Journal of Dentistry
Table 1: GCF volume (μL) of diseased and nondiseased sites in 12 periodontal patients prior to and following therapy.
Periodontal
sites
Baseline
(mean ± SD)
6w e e k s
(mean ± SD)
16 weeks
(mean ± SD)
32 weeks
(mean ± SD)
Diseased 0.186 ±0.042
∗∗ 0.05 ±0.013
∗ 0.032 ±0.014
∗ 0.036 ±0.013
∗
Nondiseased 0.033 ±0.012 0.014 ±0.005 0.016 ±0.007 0.013 ±0.006
∗P<0.05 between diseased and nondiseased sites.
∗∗P<0.01 between diseased and nondiseased sites.
Table 2: Concentration and total amount of IL-6 and IL-8 in GCF as well as PD, CAL, PlI, and GI prior to and following therapy in diseased
and nondiseased sites of 12 periodontal patients.
Parameters Baseline
(Mean ± SD)
6w e e k s
(Mean ± SD)
16 weeks
(Mean ± SD)
32 weeks
(Mean ± SD)
IL-6 D 11.38 ±4.73
∗∗## 33.56 ±10.54
∗ 33.12 ±12.86
∗ 38.72 ±11.77
∗
IL-6 ND 79.42 ±34.21
∗∗ 82.60 ±37.52
∗ 68.37 ±18.12
∗ 93.63 ±24.04
∗
TAIL-6 D 1.06 ±0.41 0.88 ±0.37 0.79 ±0.27 1.03 ±0.27
TAIL-6 ND 1.39 ±0.56 0.97 ±0.35 0.99 ±0.31 1.25 ±0.39
IL-8 D 1103.76 ±498.22
∗∗# 2085.27 ±664.01
∗∗# 3243.4 ±2271.12 3290.47 ±609.77
IL-8 ND 3957.32 ±1983.64
∗∗ 5495.88 ±1985.74
∗∗ 4269.38 ±2607.36 4692.78 ±1267.21
TAIL-8 D 95.51 ±40.03## 59.68 ±24.78 62.63 ±17.87 71.32 ±14.64
TAIL-8 ND 101.97 ±39.10## 58.12 ±19.62 50.16 ±10.37 54.96 ±13.06
PD-D 6.10 ±0.87
∗∗## 3.83 ±1.16
∗∗ 3.46 ±0.96
∗∗ 3.57 ±1.04
∗∗
PD-ND 2.42 ±0.58
∗∗ 2.17 ±0.56
∗∗ 2.29 ±0.46
∗∗ 2.29 ±0.55
∗∗
CAL-D 7.35 ±1.68
∗∗## 5.93 ±1.92
∗∗ 5.57 ±1.93
∗∗ 5.755 ±1.80
∗∗
CAL-ND 3.42 ±1.28
∗∗ 3.58 ±1.18
∗∗ 3.75 ±1.11
∗∗ 3.58 ±1.14
∗∗
PlI-D 2.07 ±0.51
∗∗## 0.71 ±0.46
∗∗# 0.26 ±0.44# 0.57 ±0.53
∗∗
PlI-ND 1.21 ±0.41
∗∗## 0.33 ±0.48
∗∗# 0.08 ±0.28# 0.29 ±0.46
∗∗
GI-D 2.08 ±0.28
∗∗## 0.67 ±0.58
∗∗# 0.11 ±0.32# 0.44 ±0.50
∗∗
GI-ND 1.00 ±0.00
∗∗## 0.17 ±0.38
∗∗# 0.00 ±0.00 0.04 ±0.20
∗∗
D: diseased sites; ND: nondiseased sites; IL-6, IL-8: concentration (pg/μL); TAIL-6, TAIL-8: total amount (pg/30s).
∗P<0.05 between diseased and nondiseased sites.
∗∗P<0.01 between diseased and nondiseased sites.
#P<0.05 between two examination intervals.
##P<0.01 between two examination intervals.
Table 3: Correlation between total amount and concentration of
IL-6 and IL-8.
IL-6 TAIL-6 IL-8 TAIL-8
IL-6 1.000
TAIL-6 0.412 1.000
IL-8 0.385
∗ 0.164 1.000
TAIL-8 −0.189 0.237 0.439 1.000
∗P<0.05; IL-6, IL-8: concentration (pg/μL); TAIL-6, TAIL-8: total amount
(pg/30s).
(signiﬁcantlyindiseasedsitesat6weeks,P<0.05).Similarly,
IL-6 concentration was higher in nonsmokers compared to
smokers without reaching statistical signiﬁcance.
At baseline, in all sites TAIL-8 levels were higher in
nonsmokers (signiﬁcantly P<0.01 in nondiseased sites).
Periodontal treatment led to reduced TAIL-8 levels in
nonsmokers, while it did not seem to inﬂuence them in
Table 4: Correlation between concentration, total amount of IL-6
and IL-8, and clinical parameters of 12 periodontal patients.
Parameters IL-6 IL-8 TAIL-6 TAIL-8
PlI −0.236 −0.212 0.095 0.209
GI −0.323
∗ −0.278 −0.107 0.224
PD −0.471
∗ −0.262 −0.279 −0.213
CAL −0.385
∗ −0.121 −0.114 −0.185
∗P<0.05, IL-6, IL-8: concentration (pg/μL), TAIL-6, TAIL-8: total amount
(pg/30s).
smokers. Following therapy, TAIL-8 levels were higher in
smokers compared to nonsmokers (signiﬁcantly at 32 weeks
in diseased and at 6 weeks in nondiseased sites).
Indiseasedsites,IL-8concentrationinsmokersincreased
following therapy, while it remained almost unchanged in
nonsmokers. Thus, IL-8 was signiﬁcantly higher in smokers
post-treatment (P<0.01). In nondiseased sites, IL-8 atInternational Journal of Dentistry 5
Table 5: Concentration and total amount of IL-6 and IL-8 in GCF as well as PD, CAL prior to and following therapy in diseased and
nondiseased sites of 7 smokers and 5 nonsmoker periodontal patients.
Parameters Baseline
(Mean ± SD)
6w e e k s
(Mean ± SD)
16 weeks
(Mean ± SD)
32 weeks
(Mean ± SD)
Diseased sites
IL-6 NS 15.85 ±6.03 43.16 ±11.86 32.50 ±13.32 45.57 ±12.44
IL-6 S 8.19 ±2.35 26.70 ±7.69 33.57 ±11.67 33.82 ±10.91
TAIL-6 NS 1.46 ±0.57 1.38 ±0.43
∗ 1.12 ±0.29 1.52 ±0.39
∗
TAIL-6 S 0.78 ±0.28 0.53 ±0.20
∗ 0.56 ±0.22 0.68 ±0.17
∗
IL-8 NS 1177.12 ±496.41 1168.81 ±509.83 1237.93 ±337.84 1167.10 ±305.47
IL-8 S 1051.36 ±501.22## 2739.87 ±823.54## 4675.88 ±1062.09 4807.16 ±938.66
TAIL-8 NS 118.89 ±44.51 42.67 ±17.18 40.66 ±11.31 41.63 ±9.87
∗
TAIL-8 S 78.80 ±27.04 71.83 ±30.45 78.32 ±19.96 92.52 ±20.94
∗
PD-NS 6.03 ±0.81 3.67 ±1.03 3.30 ±0.79 3.27 ±1.05
∗
PD-S 7.52 ±1.85 3.95 ±1.25 3.57 ±1.06 3.79 ±1.02
∗
CAL-NS 7.10 ±1.40 5.53 ±1.61 5.03 ±1.63 5.13 ±1.61
∗
CAL-S 7.52 ±1.85 6.21 ±2.08 5.95 ±2.05 6.19 ±1.81
∗
Nondiseased sites
IL-6 NS 102.46 ±41.36 92.23 ±42.07 46.46 ±12.53 106.38 ±27.89
IL-6 S 62.97 ±27.26 75.74 ±17.89 84.03 ±22.75 84.53 ±20.11
TAIL-6 NS 1.93 ±0.62 1.22 ±0.41 1.20 ±0.36 1.77 ±0.48
TAIL-6 S 1.01 ±0.41 0.79 ±0.20 0.84 ±0.18 0.88 ±0.30
IL-8 NS 6010.00±2028.23
∗∗## 2656.83 ±1001.99
∗ 1624.08 ±337.90
∗∗ 2542.74 ±679.54
∗∗
IL-8 S 2491.06 ±793.85
∗∗## 7523.77 ±2898.40
∗ 6158.88 ±1095.12
∗∗ 6228.52 ±1809.06
∗∗
TAIL-8 NS 178.59 ±53.09
∗∗ 36.98 ±11.87
∗ 35.49 ±8.06 41.89 ±10.04
TAIL-8 S 47.24 ±21.38
∗∗ 73.20 ±27.11
∗ 60.64 ±11.23 64.29 ±17.43
PD-NS 2.30 ±0.67 2.10 ±0.32 2.00 ±0.00
∗ 2.00 ±0.47
∗
PD-S 2.50 ±0.52 2.21 ±0.70 2.50 ±0.52
∗ 2.50 ±0.52
∗
CAL-NS 3.20 ±1.03 3.20 ±1.03 3.40 ±0.97 3.40 ±0.84
CAL-S 3.57 ±1.45 3.86 ±1.23 4.00 ±1.18 3.71 ±1.33
NS: nonsmokers; S: smokers, IL-6, IL-8: concentration (pg/μL); TAIL-6, TAIL-8: total amount (pg/30s);
∗P<0.05 between smokers and nonsmokers.
∗∗P<0.01 between smokers and nonsmokers.
##P<0.01 between two examination intervals.
baseline was higher in nonsmokers (P<0.01), while
following therapy IL-8 was higher in smokers (P<0.01).
4. Discussion
The major pathophysiological role of interleukin-8 lies in
aﬀecting neutrophils [15, 37]. IL-8 levels in GCF, therefore,
from patients during periodontal therapy could be helpful
in monitoring the progression of periodontal disease. In
our study, no clear diﬀerences in the total amount of IL-
8 were observed, when diseased sites were compared with
nondiseased ones implying either the inﬂammatory status of
“healthy” sites or the role of IL-8 to the steady state of the
gingival [38]. Additionally, the ﬁndings of previous studies
[14, 39] suggested an inverse relationship between PMN
recruitment responsible for the periodontal status and IL-8
levels in GCF. Mathur et al. [16], on the contrary, found that
the total amount of IL-8 was higher in diseased compared to
healthy sites. Periodontal treatment resulted in a signiﬁcant
decrease of mean TAIL-8 in diseased and nondiseased sites
at 6 weeks. However, at that time, in 23 of the 72 diseased
sites an increase of TAIL-8 was noted. Chung et al. [14]
found that in some patients scaling and root planing led
to decreased and in some others to increased levels of IL-
8a n do fβ-glucuronidase, a PMN indicator, and tried to
correlate them with individuals at risk for progression of
periodontitis.Inourstudy,thesiteswithincreasedIL-8levels
following therapy were not characterized by signiﬁcant loss
of attachment or inﬂammation. Weak correlations between
TAIL-8 and clinical parameters were observed, positive with
GI and negative with PD. This could be explained by the
fact that clinical parameters, such as probing depth, clinical
attachment loss, and bleeding on probing do not necessarily
reﬂect current disease activity [38] as well as by the small
number of patients and their heterogeneity. Both treatment
modalities, surgical and nonsurgical, improved the clinical
indices and resulted in lower TAIL-6 and TAIL-8 levels 6
weeks following therapy. At 32 weeks, these levels increased.6 International Journal of Dentistry
At that time, however, the levels were similar in surgically
and nonsurgically treated sites. These data suggest that in
this split-mouth design research, where factors inﬂuencing
the one half of the mouth might also inﬂuence the other half,
thetreatmentmodalitydidnotinﬂuencetheamountsofIL-6
and IL-8 in GCF 32 weeks following therapy.
The concentrations of both IL-6 and IL-8 were sig-
niﬁcantly higher in nondiseased compared to diseased
sites, while following periodontal treatment they increased
signiﬁcantly. These results could be due to the reduction
of GCF volume following successful therapy. It has been
suggested that in GCF the total cytokine amount might be
more representative of the disease status as compared to the
concentration [40]. According to Chapple et al. [41], GCF
volumesareveryvariableirrespectiveofinﬂammatorystatus.
Thus, it was proposed [41] that the total marker activity per
30s GCF sample rather than the concentration of the marker
might provide a better correlation with health or disease
status.
IL-6 has direct stimulatory eﬀects on bone resorption
[42], although this is controversial [43]. On the other hand,
IL-6 was suggested to have anti-inﬂammatory properties
[27]. In our study, neither disease severity nor inﬂammatory
status seemed to inﬂuence signiﬁcantly TAIL-6 levels. There
was a weak negative correlation between TAIL-6 and PD or
GI, while in nondiseased sites, mean TAIL-6 was numerically
higher compared to diseased sites. Following treatment,
TAIL-6 levels were slightly reduced at 6 and at 16 weeks.
According to our ﬁndings, the total amounts of GCF
IL-6 could hardly be correlated with either periodontal
destruction or inﬂammation. In agreement with our results,
Bozkurt et al. [44] suggested that in patients with adult
periodontitis no correlation between GCF IL-6 levels and
clinical parameters was found. However, previous results
suggested a positive correlation of TAIL-6 with disease
activity [45]. Geivelis et al. [46] found signiﬁcant positive
correlations between gingival bleeding as well as PD and
IL-6. Atilla and K¨ ut¨ ukc ¸¨ uler [47] detected higher GCF IL-
6 levels in sites with gingivitis than in healthy ones, while
Lee et al. [48] indicated higher GCF IL-6 levels in active
than in inactive sites. The diversity of the results in diﬀerent
studiessupporttheideathattheproductionofinﬂammatory
mediators diﬀers from site to site and from subject to subject
and their levels may be inﬂuenced by several factors, such as
genetic factors [49] and bacterial composition [50].
Smoking is an important environmental risk factor for
the initiation and progression of periodontitis [51–53]. In
agreement with previous ﬁndings [53], our results showed
that smoking did not inﬂuence signiﬁcantly IL-6 levels in
GCF, although there was a trend for higher IL-6 levels in
nonsmokers compared to smokers, signiﬁcantly at 6 weeks
following therapy. Before treatment, when the antigenic
stimuli from the bacterial plaque in untreated periodontal
pockets were high, the total amounts of IL-8 were higher in
nonsmokers than in smokers. Following therapy, IL-8 levels
decreased signiﬁcantly in nonsmokers; on the contrary, they
did not seem to be inﬂuenced in smokers. As a consequence,
TAIL-8 levels were higher in smokers following treatment
comparedtononsmokers,asitwassuggestedfromaprevious
study on experimental gingivitis [54]. The concentration of
IL-8 in nonsmokers remained almost unchanged following
therapy, while in smokers it increased steadily and became
signiﬁcantlyhigherthaninnonsmokers.Althoughonecould
consider the small number of patients studied, when inter-
preting the results, our observations suggest that smoking
may keep the GCF content of IL-8 in high levels inﬂuencing
theresponsetoperiodontaltherapy.Additionally,indiseased
sites a better clinical result was achieved in nonsmokers
following treatment, as evident from the PD and CAL
values. This is in agreement with previous observations
that the outcome of periodontal therapy was signiﬁcantly
compromised in smokers [51, 52, 55].
5. Conclusions
Both treatment modalities improved signiﬁcantly the clinical
indicies; this improvement was accompanied by a down
regulationofthemeantotalamountofIL-8inGCF.Thetotal
amounts of IL-6, however, were not signiﬁcantly inﬂuenced
during the 32 weeks following therapy. A strong relation-
ship between IL-6 or IL-8 levels in GCF and periodontal
destruction or inﬂammation was not found. Moreover, the
smoking status seemed to inﬂuence both the total amount
and the concentration of IL-8 in diseased and nondiseased
s i t e sa sw e l la sI L - 6l e v e l st oal e s s e re x t e n d .T h ev a l u eo f
monitoring GCF IL-6 and IL-8 was not evident in our study;
further studies are required to clarify the exact role of these
cytokines in periodontal disease and to evaluate other factors
that in conjunction with local ones may inﬂuence their levels
in GCF.
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